TMCI - Treace Medical Concepts, Inc. Stock Price, Fair Value and News

4.99USD-0.64 (-11.37%)Delayed

Market Summary

USD4.99-0.64

Delayed

-11.37%

TMCI Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

TMCI Stock Price

View Fullscreen

TMCI RSI Chart

TMCI Valuation

Market Cap

309.4M

Price/Earnings (Trailing)

-5.65

Price/Sales (Trailing)

1.58

Price/Free Cashflow

-8.06

TMCI Price/Sales (Trailing)

TMCI Profitability

Return on Equity

-43.32%

Return on Assets

-22.56%

Free Cashflow Yield

-12.41%

TMCI Fundamentals

TMCI Revenue

Revenue (TTM)

196.0M

Rev. Growth (Yr)

21.12%

Rev. Growth (Qtr)

-17.85%

TMCI Earnings

Earnings (TTM)

-54.7M

Earnings Growth (Yr)

-38.81%

Earnings Growth (Qtr)

-197.34%

Breaking Down TMCI Revenue

Last 7 days

13.9%

Last 30 days

-56.2%

Last 90 days

-67.8%

Trailing 12 Months

-81.1%

How does TMCI drawdown profile look like?

TMCI Financial Health

Current Ratio

3.98

Debt/Equity

0.42

Debt/Cashflow

-0.46

TMCI Investor Care

Shares Dilution (1Y)

1.10%

Diluted EPS (TTM)

-0.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	196.0M	0	0	0
2023	155.0M	167.0M	174.7M	187.1M
2022	104.8M	114.1M	125.5M	141.8M
2021	64.8M	77.7M	85.1M	94.4M
2020	43.9M	48.4M	52.9M	57.4M
2019	0	0	0	39.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Treace Medical Concepts, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 10, 2024	scanlan sean f.	sold (taxes)	-	-	-1,396	chief innovation officer
Mar 10, 2024	berutti aaron	sold (taxes)	-	-	-1,815	svp, sales
Mar 10, 2024	elder scot michael	sold (taxes)	-	-	-1,666	chief legl & comp off, corpsec
Mar 10, 2024	treace john t.	sold (taxes)	-	-	-5,021	chief executive officer
Mar 10, 2024	hair mark	sold (taxes)	-	-	-4,088	chief financial officer
Mar 08, 2024	hair mark	sold (taxes)	-	-	-1,067	chief financial officer
Mar 08, 2024	scanlan sean f.	sold (taxes)	-	-	-389	chief innovation officer
Mar 08, 2024	elder scot michael	sold (taxes)	-	-	-169	chief legl & comp off, corpsec
Mar 08, 2024	berutti aaron	sold (taxes)	-	-	-711	svp, sales
Mar 08, 2024	treace john t.	sold (taxes)	-	-	-2,064	chief executive officer

Which funds bought or sold TMCI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	new	-	816	816	-%
May 16, 2024	Grandeur Peak Global Advisors, LLC	added	160	451,040	721,391	0.06%
May 16, 2024	AWM Investment Company, Inc.	new	-	717,750	717,750	0.09%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.03	-17,333	602,062	-%
May 16, 2024	JANE STREET GROUP, LLC	added	53.43	147,290	405,503	-%
May 15, 2024	Quarry LP	new	-	24,834	24,834	-%
May 15, 2024	Squarepoint Ops LLC	reduced	-77.38	-1,276,360	384,584	-%
May 15, 2024	Cubist Systematic Strategies, LLC	new	-	3,340,760	3,340,760	0.02%
May 15, 2024	TWO SIGMA ADVISERS, LP	new	-	399,330	399,330	-%
May 15, 2024	Alyeska Investment Group, L.P.	reduced	-13.9	-275,753	2,046,180	0.01%

Are Funds Buying or Selling TMCI?

Are funds buying TMCI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TMCI

No. of Funds

Unveiling Treace Medical Concepts, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	alliancebernstein l.p.	0.1%	62,130	SC 13G/A
Feb 13, 2024	vanguard group inc	6.96%	4,293,789	SC 13G/A
Feb 09, 2024	treace john t.	17.7%	10,903,466	SC 13G/A
Jan 29, 2024	blackrock inc.	6.0%	3,691,901	SC 13G
Feb 14, 2023	alliancebernstein l.p.	5.8%	3,196,422	SC 13G
Feb 13, 2023	treace john r	4.3%	2,385,033	SC 13G/A
Feb 13, 2023	treace john t.	19.6%	10,865,584	SC 13G/A
Feb 09, 2023	vanguard group inc	5.90%	3,276,849	SC 13G
Feb 11, 2022	treace john t.	20.2%	10,746,709	SC 13G
Feb 11, 2022	treace john r	6.4%	3,410,043	SC 13G

Recent SEC filings of Treace Medical Concepts, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 09, 2024	S-8	Employee Benefits Plan
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report

Peers (Alternatives to Treace Medical Concepts, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Treace Medical Concepts, Inc. News

Latest updates

Treace Medical Concepts, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-17.8%	51.00	62.00	41.00	42.00	42.00	50.00	33.00	30.00	29.00	33.00	22.00	21.00	19.00	24.00	14.00	8.00	11.00	-
Gross Profit	-19.2%	41.00	51.00	33.00	34.00	34.00	41.00	27.00	25.00	24.00	28.00	17.00	17.00	15.00	19.00	11.00	6.00	9.00	-
Operating Expenses	4.2%	60.00	58.00	51.00	47.00	48.00	44.00	38.00	37.00	32.00	34.00	23.00	21.00	17.00	15.00	11.00	7.00	10.00	-
S&GA Expenses	1.0%	40.00	40.00	34.00	34.00	34.00	30.00	26.00	27.00	22.00	23.00	16.00	14.00	12.00	11.00	8.00	5.00	7.00	-
R&D Expenses	26.7%	5.00	4.00	4.00	4.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	1.00	1.00	-
Interest Expenses	1.0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	-
Net Income	-197.3%	-18.68	-6.28	-17.52	-12.27	-13.45	-4.41	-12.13	-17.23	-9.04	-6.62	-6.42	-5.08	-2.43	3.00	-2.65	-1.97	-1.61	-
Net Income Margin	-5.5%	-0.28*	-0.26*	-0.27*	-0.25*	-0.30*	-0.30*	-0.36*	-0.34*	-0.26*	-0.22*	-0.13*	-0.10*	-	-	-	-	-	-
Free Cashflow	-549.7%	-11.15	-1.72	-13.01	-12.53	-18.78	-7.68	-13.35	-15.73	-8.72	-4.65	-10.18	-4.42	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-3.6%	243	252	240	250	249	159	156	159	147	141	138	142	37.00	42.00
Current Assets	-5.5%	187	198	187	198	223	133	128	135	127	138	135	141	36.00	41.00
Cash Equivalents	-28.1%	9.00	13.00	7.00	12.00	30.00	19.00	89.00	102	98.00	106	109	120	16.00	18.00
Inventory	22.6%	36.00	29.00	29.00	26.00	23.00	19.00	17.00	13.00	11.00	11.00	10.00	8.00	7.00	8.00
Net PPE	10.0%	25.00	22.00	22.00	19.00	16.00	15.00	14.00	9.00	4.00	3.00	2.00	1.00	1.00	1.00
Goodwill	0%	13.00	13.00	13.00	13.00	-	-	-	-	-	-	-	-	-	-
Liabilities	2.1%	116	114	103	100	92.00	98.00	94.00	87.00	60.00	48.00	40.00	39.00	38.00	41.00
Current Liabilities	4.5%	47.00	45.00	33.00	30.00	23.00	30.00	23.00	17.00	15.00	18.00	11.00	10.00	9.00	12.00
Long Term Debt	0.1%	53.00	53.00	53.00	53.00	53.00	53.00	53.00	53.00	29.00	29.00	29.00	29.00	29.00	29.00
LT Debt, Non Current	-100.0%	-	53.00	53.00	53.00	53.00	53.00	53.00	53.00	29.00	29.00	29.00	29.00	29.00	29.00
Shareholder's Equity	-8.4%	126	138	138	150	158	61.00	62.00	72.00	87.00	93.00	97.00	103	-	1.00
Retained Earnings	-13.9%	-152	-134	-127	-110	-98.17	-84.72	-80.30	-68.20	-50.90	-41.90	-35.29	-28.87	-23.78	-21.35
Additional Paid-In Capital	2.7%	279	272	266	261	256	145	142	140	138	135	133	132	15.00	14.00
Shares Outstanding	0.3%	62.00	62.00	62.00	62.00	61.00	56.00	55.00	55.00	55.00	48.00	53.00	49.00	-	-
Float	-	-	-	-	1,224	-	-	-	526	-	-	-	1.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-1457.3%	-7,221	532	-9,507	-8,300	-17,300	-5,348	-7,493	-10,566	-7,241	-3,752	-9,241	-3,754	-446	2,442	-4,202	-1,845	-895	-
Share Based Compensation	26.2%	7,408	5,872	5,192	3,596	2,692	2,470	2,269	1,963	1,409	1,293	839	875	402	337	125	248	209	-
Cashflow From Investing	-24.9%	3,758	5,007	4,597	-10,423	-80,480	-64,012	-5,857	-5,168	-1,481	-900	-939	-670	-196	-88.00	-58.00	-249	-674	-
Cashflow From Financing	-212.1%	-185	165	159	1,180	107,879	297	353	18,784	1,372	1,026	41.00	107,804	-1,219	323	9,351	1,796	33.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TMCI Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 51,108	$ 42,195
Cost of goods sold	10,127	8,039
Gross profit	40,981	34,156
Operating expenses
Sales and marketing	40,328	33,655
Research and development	5,259	3,412
General and administrative	14,362	10,865
Total operating expenses	59,949	47,932
Loss from operations	(18,968)	(13,776)
Interest income	1,535	1,479
Interest expense	(1,317)	(1,285)
Other income, net	74	128
Other non-operating income (expense), net	292	322
Net loss	(18,676)	(13,454)
Unrealized gain (loss) on marketable securities	(94)	(29)
Comprehensive loss	$ (18,770)	$ (13,483)
Net loss per share attributable to common stockholders, basic	$ (0.3)	$ (0.23)
Net loss per share attributable to common stockholders, diluted	$ (0.3)	$ (0.23)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	61,792,788	58,723,760
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	61,792,788	58,723,760

TMCI Balance Sheet

2024-03-31

Condensed Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 9,334	$ 12,982
Marketable securities, short-term	100,672	110,216
Accounts receivable, net of allowance for doubtful accounts of $1,076 and $980 as of March 31, 2024 and December 31, 2023, respectively	30,083	38,063
Inventories	35,860	29,245
Prepaid expenses and other current assets	11,448	7,853
Total current assets	187,397	198,359
Property and equipment, net	24,517	22,298
Intangible assets, net of accumulated amortization of $713 and $475 as of March 31, 2024 and December 31, 2023, respectively	8,787	9,025
Goodwill	12,815	12,815
Operating lease right-of-use assets	9,064	9,264
Other non-current assets	146	146
Total assets	242,726	251,907
Current liabilities
Accounts payable	21,149	11,835
Accrued liabilities	15,155	10,458
Accrued commissions	5,527	10,759
Accrued compensation	4,196	7,549
Other liabilities	1,022	4,432
Total current liabilities	47,049	45,033
Long-term debt, net of discount of $917 and $992 as of March 31, 2024 and December 31, 2023, respectively	53,083	53,008
Operating lease liabilities, net of current portion	16,166	15,891
Other long-term liabilities	37	37
Total liabilities	116,335	113,969
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, $0.001 par value,5,000,000 shares authorized as of March 31, 2024 and December 31,2023 ;0 shares issued and outstanding as of March 31,2024 and December 31, 2023	0	0
Common stock, $0.001 par value, 300,000,000 shares authorized; 61,948,776 and 61,749,654 issued, and 61,929,172 and 61,749,654 outstanding as of March 31, 2024 and December 31, 2023, respectively	62	62
Additional paid-in capital	279,433	271,973
Accumulated deficit	(152,923)	(134,247)
Accumulated other comprehensive (loss) income	69	163
Treasury stock,at cost; 19,604 and 1,218 shares as of March 31, 2024 and December31, 2023,respectively	(250)	(13)
Total stockholders’ equity	126,391	137,938
Total liabilities and stockholders’ equity	$ 242,726	$ 251,907

About Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision; and Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

CEO	Mr. John T. Treace
WEBSITE	treace.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	423

Treace Medical Concepts, Inc. Frequently Asked Questions

What is the ticker symbol for Treace Medical Concepts, Inc.? What does TMCI stand for in stocks?

TMCI is the stock ticker symbol of Treace Medical Concepts, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Treace Medical Concepts, Inc. (TMCI)?

As of Fri May 17 2024, market cap of Treace Medical Concepts, Inc. is 309.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TMCI stock?

You can check TMCI's fair value in chart for subscribers.

What is the fair value of TMCI stock?

You can check TMCI's fair value in chart for subscribers. The fair value of Treace Medical Concepts, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Treace Medical Concepts, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TMCI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Treace Medical Concepts, Inc. a good stock to buy?

The fair value guage provides a quick view whether TMCI is over valued or under valued. Whether Treace Medical Concepts, Inc. is cheap or expensive depends on the assumptions which impact Treace Medical Concepts, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TMCI.

What is Treace Medical Concepts, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TMCI's PE ratio (Price to Earnings) is -5.65 and Price to Sales (PS) ratio is 1.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TMCI PE ratio will change depending on the future growth rate expectations of investors.